APPLICABILITY OF BIOMEDICAL PRODUCTS IN PATIENTS WITH DIABETIC FOOT SYNDROME
https://doi.org/10.24884/2072-6716-2020-21-4-63-69
Abstract
Fast and cost-effective treatment of patients with diabetic foot syndrome (DFS) is still a great challenge today. The use of biomedical cell products (BCP) in this category of patients has its own pathogenetic orientation, however, it remains not fully understood and accepted. This review presents the results of numerous studies confirming the effectiveness of the use of BCP for the treatment of mainly superficial trophic defects in patients with neuropathic form of DFS. However, these technologies are still behaved to adjuvant therapies. There are no clear algorithms and regulations for the use of BCP in patients with DFS. It was shown that use of BCP accelerates the reparative processes of superficial trophic defects in patients with neuropathic form of DFS in combination with standard therapy and reduces the time of wound epithelization. In view of the complexity and high cost of BCP, it should be considered the possibility of their use in patients with a neuroischemic form of DFS of different grades by WIfI classification.
About the Authors
A. A. Kolke
St. Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
St. Petersburg
E. V. Zinoviev
St. Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
V. V. Zavatskii
St. Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. IDF Diabetes Atlas, 9th ed. Brussels, Belgium: International Diabetes Federation. 2019.
2. Patel S., Srivastava S., Singh M. R., Singh D. Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing // Biomedicine & Pharmacotherapy. 2019. Vol. 112. 108615.
3. Park K. H., Kwon J. B., Park J. H. et al. Collagen dressing in the treatment of diabetic foot ulcer: A prospective, randomized, placebo-controlled, single-center study // Diabetes Research and Clinical Practice. 2019. Vol. 156.
4. Armstrong D. G., Wrobel J., Robbins J. M. et al. Guest editorial: are diabetes-related wounds and amputations worse than cancer? // Int. Wound. J. 2007. Vol. 4, No 4. P. 286–287.
5. Bakker K., Apelqvist J., Lipsky B. A. et al. Manual and documents of International Working Group on the Diabetic Foot 2015 for prevention and treatment of diabetic foot diseases: the achievement of argumentative consensus (Russian cut version). Wounds and wound infections. The prof. B. M. Kostyuchenok journal. 2016. Vol. 3, No 2, pp. 59–70.
6. Meggitt B. Surgical management of the diabetic foot // Br. J. Hosp. Med. 1976. Vol. 16. P. 227–232.
7. Galstyan G. R., Tokmakova A. Yu., Egorova D. N. et al. Clinical guidelines for diagnosis and treatment of diabetic foot syndrome. Wounds and wound infections. The prof. B. M. Kostyuchenok journal. 2015. Vol. 3 (In Russ.).
8. Tupikin R. S., Chibirov S. K., Zebelyan A. A. et al. Modern classification of diabeticfoot SVS WIFI. Innovative medicine of Kuban. 2018. Vol. 2, pp. 73–78 (In Russ.).
9. Presented at a plenary session of the 2014 Vascular Annual Meeting of the Society for Vascular Surgery, Vascular and Endovascular Surgery Society Session The Society for Vascular Surgery lower extremity threatened limb classification system based on Wound, Ischemia, and foot Infection (WIfI) correlates with risk of major amputation and time to wound healing // Journal of Vascular Surgery. 2014. Vol. 61. P. 939–944.
10. International Working Group on the Diabetic Foot. IWGDF Guidelines on the prevention and management of diabetic foot disease. 2019.
11. Giannopoulos S., Armstrong E. J. Diabetes mellitus: an important risk factor for peripheral vascular disease // Expert Review of Cardiovascular Therapy. 2020. Vol. 18, No. 3. P. 131–137.
12. Kalinin R., Suchkov I., Mzhavanadze N. et al. Regenerative technologies in treatment of diabetic foot ulcers. Genes and Cells, 2017, Vol. 12, No 1, pp. 15–26 (In Russ.).
13. Meloni M., Izzo V., Giurato L. et al. Recurrence of Critical Limb Ischemia After Endovascular Intervention in Patients with Diabetic Foot Ulcers // Adv. Wound Care (New Rochelle). 2018. Vol. 7, No. 6. P. 171–176.
14. Frykberg R. G. Management of Diabetic Foot Ulcers: A Review // Federal practitioner: for the health care professionals of the VA, DoD, and PHS. 2016. Vol. 33, No 2. P. 16–23.
15. Pickwell K. M., Siersma V. D., Kars M. et al. Diabetic foot disease: impact of ulcer location on ulcer healing Diabetes // Metab. Res. Rev. 2013. Vol. 29. P. 377–338.
16. Everett Е., Mathioudakis N. Update on management of diabetic foot ulcers // Journal Annals of New York Academy of Sсinces. 2018. Vol. 1411, No 1. P. 153–165.
17. Schultz G. S. et al. Wound bed preparation: A systematic approach to wound management // Wound Repair Regen. 2003. Vol. 11, No 1. P. 1–28.
18. Zayceva E. L. Clinical, morphological and immunohistochemical features of soft tissue repair of the lower extremities in patients with diabetic foot syndrome against the background of various methods of local treatment: dis. … сand. med. sciences. 2015 (In Russ.).
19. Efimov E. V., Khoroshkevich A. V. Features of wound process affected bydiabetes mellitus. Wounds and wound infections. The prof. B. M. Kostyuchenok journal, 2015, Vol. 2, No 3, pp. 30–35 (In Russ.).
20. Stupin V. A., Gabitov R. B., Sinelnikova T. G., Silina E. V. Biological mechanisms of chronic wound and diabetic foot healing: the role of collagen // Ser. J. Exp. Clin. Res. 2018. Vol. 19, No 4. P. 373–382.
21. Vagner D. O., Zinoviev E. V., Krylov K. M. et al. Experience in the clinical use of allogeneic fibroblasts in patients with severe burns. Herald of North-Western State Medical University named after I. I. Mechnikov, 2018, Vol. 10, No 3, pp. 65–72 (In Russ.).
22. Binienko M. A., Kotslova A. A., Davydenko V. V., Vlasov T. D. Application oggraftskin to acceleratehealing of ulcersin diabetic foot syndrome. Grekov’s Bulletin of Surgery, 2016, Vol. 175, No 5, pp. 63–68 (In Russ.).
23. Zelen C. M., Orgill D. P., Serena T. et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers // International Wound Journal. 2017. Vol. 14, No 2. P. 307–315.
24. Martinson M., Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers // Journal of wound care North American Supplement. 2016. Vol. 25, No 10. P. 8–17.
25. Blinova I. M., Udintsev N. M., Aleksandrova O. I. et al. Clinical experience healing of venous ulcers with the use of a cellular product “The dermal equivalent ED”. Health — the base of humanpotential: problem sandways to solve them. 2015. Vol. 10, No 2, pp. 690–694 (In Russ.).
Review
For citations:
Kolke A.A., Zinoviev E.V., Zavatskii V.V. APPLICABILITY OF BIOMEDICAL PRODUCTS IN PATIENTS WITH DIABETIC FOOT SYNDROME. EMERGENCY MEDICAL CARE. 2020;21(4):63-69. (In Russ.) https://doi.org/10.24884/2072-6716-2020-21-4-63-69
Views:
448
Email this article 